Stempoint Capital’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
Stempoint Capital's ACRS Position: Q3 2026 in Review
Stempoint Capital opened a new position in Aclaris Therapeutics (ACRS) in Q3 2026: 2,050,698 shares worth $10.8M. The stake represents 1.93% of the portfolio and ranks #18 among its holdings.
167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- Stempoint Capital held 2,050,698 shares of Aclaris Therapeutics worth $10.8M as of Q3 2026.
- Aclaris Therapeutics was a new Stempoint Capital position in Q3 2026.
- Aclaris Therapeutics made up 1.93% of Stempoint Capital's portfolio in Q3 2026, its #18 holding.
- 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on Stempoint Capital's 13F filing for Q3 2026, filed 16 Nov 2026.